文献速递糖尿病

G6PD缺乏及东南亚特异性突变降低泰国人群HbA1c水平:对糖尿病诊断的启示

Glucose 6-phosphate dehydrogenase deficiency and Southeast Asian-specific mutations lower HbA1c levels in a Thai population: implications for diabetes diagnosis.
PubMed 文献 · Diabetologia · 2025-09-01

该横断面研究纳入1007名健康医院职工,发现G6PD缺乏者及携带G6PD ViangchanG871A、G6PD MahidolG487A突变者的HbA1c水平显著低于G6PD正常者,且HbA1c与G6PD活性正相关。使用突变特异性HbA1c切点可使糖尿病诊断比例不变,但糖尿病前期诊断比例从8.2%升至18.4%(酶法)和从9.2%升至21.4%(HPLC)。

要点

  • G6PD缺乏及ViangchanG871A、MahidolG487A突变者HbA1c显著降低。
  • HbA1c与G6PD活性呈正相关(r=0.208~0.211)。
  • 东南亚人群用HbA1c诊断糖尿病需考虑G6PD状态及突变。

核心结论

  • HbA1c水平与G6PD活性正相关,G6PD缺乏及ViangchanG871A、MahidolG487A突变者HbA1c显著降低。
  • 在东南亚人群中用HbA1c诊断2型糖尿病时需考虑G6PD缺乏及突变。

研究设计与样本

  • 横断面研究,纳入1007名健康医院职工,排除糖尿病、使用降糖药及影响红细胞周转的情况。
  • HbA1c用酶法和HPLC测定,G6PD活性用分光光度法分类为缺乏、中间、正常,并采用TaqMan SNP、PCR-RFLP和Sanger测序进行基因分型。

主要发现

  • G6PD缺乏者HbA1c(酶法25.68 mmol/mol[4.50%],HPLC 27.33 mmol/mol[4.65%],n=28)显著低于正常者(酶法34.05 mmol/mol[5.27%],HPLC 36.61 mmol/mol[5.50%],n=492),p<0.001。
  • G6PD ViangchanG871A携带者HbA1c(酶法29.46 mmol/mol[4.85%],HPLC 31.15 mmol/mol[5.00%],n=52)和G6PD MahidolG487A携带者(酶法28.63 mmol/mol[4.77%],HPLC 31.15 mmol/mol[5.00%],n=15)均显著低于正常者,p<0.001。
  • HbA1c与G6PD活性正相关(酶法r=0.208,HPLC r=0.211,p<0.001)。
  • G6PD突变者预测糖尿病前期的最佳HbA1c切点:酶法33至<42 mmol/mol(5.2%至<6.0%),敏感性70%,特异性88.64%,准确性86.74%;HPLC 34至<43 mmol/mol(5.3%至<6.1%),敏感性72.73%,特异性86.21%,准确性84.70%。
  • 预测糖尿病的最佳切点:酶法≥42 mmol/mol(≥6.0%),敏感性100%,特异性97.92%,准确性97.96%;HPLC≥43 mmol/mol(≥6.1%),敏感性100%,特异性96.88%,准确性96.94%。

关键数值与推荐

  • G6PD突变者糖尿病前期HbA1c切点:酶法33至<42 mmol/mol(5.2%至<6.0%);HPLC 34至<43 mmol/mol(5.3%至<6.1%)。
  • G6PD突变者糖尿病HbA1c切点:酶法≥42 mmol/mol(≥6.0%);HPLC≥43 mmol/mol(≥6.1%)。

临床怎么用

  • 在东南亚人群中使用HbA1c诊断糖尿病时,应评估G6PD缺乏及常见突变状态。
  • 对G6PD缺乏或携带ViangchanG871A、MahidolG487A突变者,可考虑采用突变特异性HbA1c切点以减少糖尿病前期漏诊。

局限性

  • 横断面设计无法推断因果关系。
  • 样本为健康医院职工,外推性受限。
  • G6PD缺乏者(n=28)及MahidolG487A突变者(n=15)样本量较小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Glucose 6-phosphate dehydrogenase (G6PD) deficiency, the most common inherited enzymopathy, can affect HbA1c levels and the diagnosis of type 2 diabetes. This cross-sectional study aimed to investigate the association between G6PD deficiency, its common mutations (G6PD ViangchanG871A, G6PD MahidolG487A) and HbA1c levels in a Thai cohort. METHODS: Blood samples from 1007 healthy hospital staff were collected during annual health checkups. Individuals with diabetes, diabetes medication use and conditions affecting erythrocyte turnover were excluded. HbA1c levels were measured by enzymatic assay and HPLC, while fasting plasma glucose (FPG) and haematological variables were obtained from checkup records. Fructosamine levels and G6PD activity (classified as deficiency, intermediate, normal) were measured by spectrophotometric assay. Genotyping was performed using TaqMan SNP, PCR-Restriction Fragment Length Polymorphism (RFLP) and Sanger sequencing. Prediabetes and diabetes were diagnosed based on two abnormal results from FPG and HbA1c at the same time, following the modified ADA criteria. Optimal HbA1c cutoffs were determined using receiver operating characteristic curve analysis with bootstrapping in RStudio, optimising Youden's index and the harmonic mean of sensitivity and specificity. RESULTS: HbA1c levels were significantly lower in individuals with G6PD deficiency (25.68 mmol/mol [4.50%] by enzymatic assay; 27.33 mmol/mol [4.65%] by HPLC; n=28; p<0.001) compared with those with normal G6PD levels (34.05 mmol/mol [5.27%] by enzymatic assay; 36.61 mmol/mol [5.50%] by HPLC; n=492). Similarly, individuals with G6PD ViangchanG871A (29.46 mmol/mol [4.85%] by enzymatic assay; 31.15 mmol/mol [5.00%] by HPLC; n=52; p<0.001) and G6PD MahidolG487A (28.63 mmol/mol [4.77%] by enzymatic assay; 31.15 mmol/mol [5.00%] by HPLC; n=15; p<0.001) had significantly lower HbA1c levels. HbA1c levels positively correlated with G6PD activity (r=0.208, p<0.001 by enzymatic assay; r=0.211, p<0.001 by HPLC). The optimal HbA1c cutoffs for predicting prediabetes in participants with G6PD mutation were 33 to <42 mmol/mol (5.2% to <6.0%) by enzymatic assay (sensitivity 70%; specificity 88.64%; accuracy 86.74%) and 34 to <43 mmol/mol (5.3% to <6.1%) measured by HPLC (sensitivity 72.73%; specificity 86.21%; accuracy 84.70%). For diabetes, the optimal cutoffs were ≥42 mmol/mol (≥6.0%) by enzymatic assay (sensitivity 100%; specificity 97.92%; accuracy 97.96%) and ≥43 mmol/mol (≥6.1%) by HPLC (sensitivity 100%; specificity 96.88%; accuracy 96.94%). Using the mutation-specific HbA1c cutoffs resulted in the proportion of individuals being diagnosed with diabetes remaining the same but the proportion diagnosed with prediabetes rose from 8.2% (ADA criteria) to 18.4% using enzymatic assay and from 9.2% to 21.4% using HPLC. CONCLUSIONS/INTERPRETATION: HbA1c levels were positively correlated with G6PD activity, with individuals carrying G6PD ViangchanG871A and G6PD MahidolG487A exhibiting significantly lower HbA1c levels. Our findings highlight the need to consider G6PD deficiency and G6PD mutations when using HbA1c to diagnose type 2 diabetes in Southeast Asian populations.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Mungkalasut P, Chanda M, Jugnam-Ang W, et al. Glucose 6-phosphate dehydrogenase deficiency and Southeast Asian-specific mutations lower HbA1c levels in a Thai population: implications for diabetes diagnosis. Diabetologia. 2025. PMID: 40887553. doi:10.1007/s00125-025-06523-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。